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Oral Presentations S227and increased physical activity (ORs 0.8-0.9; p5 0.04-0.07) were as-
sociated with a lower likelihood of requiring dyslipidemia or diabetes
medications. Obesity was significantly associated with an increased
likelihood of all 3 metabolic conditions (ORs 2.6-2.9; p\0.05). A
family history of CV disease also remained a significant risk factor
for most serious and related CV outcomes post-transplant.
Conclusions:HCT survivors have a high burden of metabolic con-
ditions (hypertension, dyslipidemia, diabetes, and obesity) known to
predispose towards more serious CV conditions following HCT. A
less healthy diet, decreased physical activity, and obesity were asso-
ciated with these conditions, suggesting potential interventions
that may reduce CV disease among HCT survivors.65
LISTEN TO THY PATIENT: POOR QUALITY OF LIFE (QoL) REPORTED BY
OLDER ADULTS PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION
(allo-HCT) IS INDEPENDENTLY ASSOCIATEDWITHWORSE TRANSPLANT
OUTCOMES
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Introduction: Concern regarding baseline health status and ability
to predict tolerance have been major factors limiting application of
allo-HCT to older adults. Standard health status assessment tools
such as comorbidity and performance status (PS), have uncertain
prognostic significance in older transplant patients. Little is known
about health related QoL in older adults undergoing allo-HCT,
and how patient perceived physical and mental functioning relates
to transplant outcomes.
Methods:We performed a prospective comprehensive geriatric as-
sessment (CGA) on patients $50 years old prior to allo-HCT. As
part of CGA, 163 patients completed a Medical Outcomes Study
Short Form (SF-36), an extensively validated health related QoL
questionnaire. Physical and mental component summary measures
(PCS andMCS) were compared to population age group norms. Ka-
plan-Meier and Cox Regression analyses were used to determine the
association between PCS and MCS as continuous variables to non-
relapse mortality (NRM) and OS. To estimate effect size, we
modeled the hazard ratio (HR) for scores \40, which represents
1SD below population norm and approximated sample median.
Results:Median age was 58; 39% were.60. AML or MDS was the
most common diagnosis (53%); 48% had active disease (not in re-
mission) prior to allo-HCT. Donor sources were matched sibling
(45%), MUD (36%), mismatch/cord (19%). Conditioning was pri-
marily reduced intensity (75% vs 25% ablative). 44% had an
HCT-CI$3; 36% had ECOG PS $1. Pre-transplant SF-36 scores
demonstrated significantly worse physical and mental health com-
pared to age group matched controls (Table 1). Lower PCS and
MCS showed borderline association with increased NRM (P5 .076
for PCS; P 5 .05 for MCS). A stronger association existed for in-
ferior survival for lower PCS (P5 .002) and MCS (P5 .014), which
remained significant when controlling for age, disease risk, co-
morbidity, and PS. PCS and MCS scores\40 reduced OS by ap-
proximately 50% (HR 1.5, 95% CI 1.03-2.3, P 5 .03 for PCS; HR
1.47, 95% CI .97-2.2, P 5 .07 for MCS).
Conclusions: Self reported physical and mental health impairments
are frequent and substantial in older adults prior to allo-HCT.
Lower physical and mental health functioning independently con-
ferred inferior OS. Patient reported functional and mental health
deficits prior to transplantation warrant study as simple and novel
prognostic markers.
Table 1. PCS and MCS Scores By Age Group
PCS PCS MCS MCSAge
Population
Mean
Sample
Mean p-valuePopulation
MeanSample
Mean p-value45-54 (n 5 46) 49.62 41.91 <.0001 50.54 38.10 <.0001
55-64 (n 5 96) 47.44 41.43 <.0001 51.71 38.06 <.0001
65-74 (n 5 24) 44.70 43.30 .52 53.17 35.94 <.000166
LONG-TERM SURVIVAL AND QUALITY OF LIFE (QoL) ASSESSMENT AFTER
REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM-CELL TRANS-
PLANTATION (SCT) FOR HEMATOLOGICAL MALIGNANCIES
Shimoni, A., Tallis, E., Shem-Tov, N., Volchek, Y., Yerushalmi, R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic SCT is associated with substantial mortality during the
first 2 years after SCT whereas after 2 years survival reaches plateau.
QoL is increasingly recognized as an important long-term end-
point. The pattern of late events and QoL has been reported follow-
ing myeloablative conditioning (MAC) but is not well defined after
reduced intensity conditioning (RIC). To explore late outcomes
we retrospectively analyzed data of 726 patients (pts) given SCT be-
tween 1/2000 and 8/2009. 246 pts were alive and disease-free 2 years
after SCT, median age 51 years (17-72). Conditioning was MAC (n
5 72), RIC (n 5 118) or reduced-toxicity myeloablative condition-
ing (RTC, n 5 56). 44 and 29% of MAC and RIC/RTC recipients
had moderate-severe (mod-sev) cGVHD (p 5 0.03) while 68 and
43% were still on immune suppressive therapy (IST) 2 years after
SCT, respectively (p5 0.001).With median follow-up of 68 months
after SCT (25-140), the probability of pts surviving disease-free 2
years after SCT to remain alive and disease-free for the next 5 years
was 84 and 82% after MAC and RIC/RTC, respectively (p 5 NS).
There were 35 deaths beyond 2 years. 20 late deaths were NRM, cu-
mulative incidence 7% after both MAC and RIC/RTC. More MAC
pts died of cGVHD/ infections (6.9 Vs 2.3%, p 5 0.08) while more
RIC/RTC pts died of second cancers (4.6 Vs 1.4%, p5NS). 24 pts
relapsed, 25-102 months after SCT, cumulative incidence 9% after
MAC and 11% after RIC/RTC (p 5 NS); 15 died. Age.55 and
mod-sev chGVHD predicted shorter survival, HR 2.1 (p 5 0.07)
and 2.6 (p 5 0.006), respectively. Mod-sev cGVHD predicted
NRM, HR 5.2 (p 5 0.001). Advanced disease predicted relapse,
HR 2.6 (p 5 0.004). Conditioning regimen was not predictive for
any of these outcomes. The probability of stopping IST by 8 years
was 59 and 75% after MAC and RIC/RTC, respectively (p 5
0.001). The median duration of IST was 30 and 20 months, respec-
tively (p5 0.05). QoLwas assessed by the EORTCQLQ-C30 ques-
tionnaire. Mean QoL score was 69, 66 and 65 after MAC, RIC and
RTC, respectively. LowQoL score was reported by 15, 14 and 19%,
respectively (p5NS).Multiple regression analysis identified contin-
uous need for IST and depression as factors correlated with a low
score while healthy lifestyle (return to work, physical and sexual ac-
tivity) and academic education correlated with high scores. In con-
clusion, late outcome is similar after MAC and RIC/RTC. Late
NRM and QoL is similar although cGVHD is less severe and IST
duration shorter after RIC/RTC.67
REACH AND UTILIZATION OF AN INTERNET SITE DESIGNED FOR HEMA-
TOPOIETIC CELL TRANSPLANTATION SURVIVORS AND TESTED IN A RAN-
DOMIZED CONTROLLED TRIAL
Yi, J.C.1, Artherholt, S.B.2, Stover, A.C.3, Flowers, M.E.D.1,
Syrjala, K.L.1 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Washington, Seattle, WA; 3University of California, San
Francisco, San Francisco, CA
Introduction: Many long-term survivors of hematopoietic cell
transplantation (HCT) struggle with health needs. The internet
may be an optimal way to reach these survivors since it can be indi-
vidualized and accessible as needed. Little is known about internet
site reach and utilization in HCT survivors. Determining the repre-
sentation of those who enroll and use an internet site is essential to
effective dissemination of these programs.
Method: All 3-18 yearHCT survivors treated at a single center were
approached for enrollment in a randomized controlled trial if they
were 18 or older, lived in the United States or Canada, had been
treated for a hematologic malignancy, their medical records did not
indicate a relapse or second cancer in the previous two years, they
had internet access, an email address and adequate English skills to
complete the assessment. Survivorswere randomly assigned to imme-
diate internet site access or delayed access after 6-month outcomes.
Results: Of 1311 approached and eligible for the study, 755 (58%)
consented and completed baseline assessment. Participants were
S228 Oral Presentationsfrom 48 states. Autologous and allogeneic HCT recipients were
equally likely to enroll (P 5 .59) and view pages (P 5 .74). Across
all races, non-white survivors were less likely to enroll compared
to whites (P\.001), but once enrolled viewed as many pages (P 5
.18). 14% were computer use beginners, 52% were intermediate
users, and 34% were experts; these groups did not differ in pages
viewed (P 5 .89). Survivors from rural versus urban areas were
equally likely to participate (P 5 .45) and utilize the site (P 5 .14).
Once randomized to site access, 70% logged on at least once. The
median number of pages visited was 7 (range 0-179). Participants
$40 years old were more likely to login at least once compared
with those\40 (P 5 .004) but age groups did not differ in pages
viewed (P5 .15). Females weremore likely to visit the site thanmales
(77% vs. 65%, P5 .007) as well as to viewmore pages (M5 21.3, SD
5 28.0 vs. M5 11.7, SD5 18.3, P\.001). Similarly, transplant sur-
vivors\10 years were more likely to enroll in the study than $10
year survivors (P\.001) but did not view more pages (P 5 .26).
Discussion: The internet provides access to long-term HCT survi-
vors.While online approaches reach a broad population and are well
utilized, additional strategies are needed for males and younger than
40 years old HCT survivors to engage them in the online resources.
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MULTI-INSTITUTIONAL EXPERIENCE OF HSCT FOR DOCK8 DEFICIENCY
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In 2009, mutations in the gene for dedicator of cytokinesis 8
(DOCK8) have been identified as the cause of the autosomal recessive
variant of Hyper-IgE syndrome. The clinical presentation of this
primary combined immunodeficiency is characterized by eczema, de-
bilitating viral infections of the skin, chronicmucocutaneous candidi-
asis, pulmonary infections, severe allergies, vascular complications
and a high risk for malignancy, mostly lymphoma or skin cancer.
While the long-term prognosis of affected patients is not yet
clearly defined, the high morbidity and mortality of this disease sug-
gest HSCT as a potential curative measure. On behalf of the EBMT
inborn errors working party we retrospectively studied the outcome
of HSCT in patients with DOCK8 mutations.
A total of fifteen patients from 10 institutions were identified, 4 of
whom had been previously reported. Three patients had malignant
disease. At a median age of 13 years (3-18) transplantation from
aMUD (n5 9), MFD (n5 2) or MSD (n5 4) was carried out. Con-
ditioning was fully myeloablative in 4, of reduced intensity in 10 or
minimal in 1. After amedian follow-up of 8months (2-89) the overall
survival is 80% (12/15). Only one patient had grade III or greater
acute GVHD; he later developed extensive chronic GVHD and
died from infection. Two other patients died, one from sepsis, the
other from progression of pre-existing lymphoma. T-cell chimerism
at last follow-up was.99% in 12/14 and 50-90% in 2/14. Of the 12
surviving patients 9 of 9 who were evaluable had complete correction
of their immunodeficiency. Other symptoms such as eczema (disap-
peared in 11/12, improved in 1/12), allergies (5/7; 2/7), mollusca (6/
8; 2/8), bacterial infections (6/6; 0/6), fungal infections (7/7; 0/7) and
pulmonary function deficits (4/4; 0/4) responded very well. One pa-
tient developed a thyroid carcinoma 7 years post transplant, likely
because of a TBI-containing conditioning regimen.Longer follow-up will be needed to ascertain that HSCT will
correct themalignancy risk, as theDOCK8molecule has been impli-
cated as a tumor suppressor and is expressed in extra-hematopoietic
tissues. A survey to define the natural course of disease and to guide
treatment recommendations for all patients is currently underway on
behalf of ESID and EBMT. In summary, HSCT corrects the immu-
nodeficiency and other disease manifestations in DOCK8 deficiency
and this treatment should be offered at least to all patients with
severe disease manifestations.
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HEMATOPOIETIC CELL TRANSPLANTATION FOR INFANTILE MALIGNANT
OSTEOPETROSIS: THE SAUDI EXPERIENCE
Al-Seraihy, A.1, Al-Hamed, M.2, Siddiqui, K.1, Al-Jefri, A.1, El-
Solh, H.1, Khairi, A.1, Al-Ahmari, A.1, Meyer, B.2, Ayas, M.1 1King
Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia;
2King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
Infantile malignant osteopetrosis (IMO) is due to a heterogeneous
group of mutations resulting in abnormal osteoclast function; more
than half of the IMO cases have mutations in the TCIRG1 gene. Al-
logeneic hematopoietic cell transplantation (HCT) is currently the
only curative therapy for IMO. We report here our experience in
IMO at King Faisal Specialist Hospital & Research Center
(KFSHRC).
Patients andMethods: Between January 1993 andDecember 2008,
25 children with IMO underwent HCT at KFSHRC, median time
from diagnosis to HCT was 3.7 month (range, 1-66 months), and
median age atHCTwas 6months, (range, 2-75months), ten patients
(40%) had severe hematopoietic deficiency, and severe visual impair-
ment at HCT. Donor source was fully matched siblings in 23 pa-
tients and partially matched unrelated cord blood in 2 patients. All
patients were conditioned with busulfan (BU) and cyclophospha-
mide (CY).
Results:Nine mutations were detected in TCIRG1, seven of which
were novel. One novel mutation was detected in CLCN7 gene.
Seven patients had no mutation detected in TCIRG1, CLCN7 or
OSTM genes. Engraftment occurred in 23 patients (92 %). Acute
GVHD and veno-occlusive disease occurred in 6 and 4 patients, re-
spectively. Seven patients (28%) had secondary graft failure at a me-
dian of 6 months post HCT (range, 3-14 months). Sixteen (64%)
patients remain alive. Chimerism studies at the last contact are avail-
able for 14 patients, and all but 2 patients have stable mixed chime-
rism. At median follow-up of 9.8 years (95% CI: 5.4-14.2 years)
ranging from 3.6 to 15.2 years, the overall survival (OS) and event-
free survival (EFS) are 55%, and 52%, respectively. All surviving pa-
tients had evidence of osteoclast function at the last evaluation, and
none of them had any further vision deterioration.
Conclusion: Children with IMO have favorable survival after allo-
geneic HCT. Although engraftment is probably not significantly af-
fected by the age, we recommend that early HCT be done to
preserve vision and final height as much as possible. Due to the small
number of patients, and the fact that a good percentage of our cases
had no mutations in the known genes, we were not able to relate
a specific genotype with outcome. However, TCIRG1 appears to
be an important gene in IMO in Saudi patients, similar to other pop-
ulations. Larger series are required to demonstrate a genotype–phe-
notype, and genotype-outcome correlation.
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HIGHLY VARIABLE PLASMA CONCENTRATIONS OF VORICONAZOLE IN
CHILDREN UNDERGOING HSCT: THERAPEUTIC DRUG MONITORING
(TDM) IS INDISPENSABLE
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Utrecht, Utrecht, Netherlands; 2UMC Utrecht, Utrecht, Netherlands
Background: Invasive fungal infections are of great concern in pedi-
atric HSCT recipients. Voriconazole is an important drug both for
prophylaxis as well as for therapy. Optimum trough levels are be-
tween 1-5 mg/l. It is unclear whether these levels are reached with
current pediatric dosing schedules. We retrospectively analysed
the use of voriconazole in our unit between 2007 and 2011.
Use of voriconazole: 92 children between 0-19 years of age under-
went HSCT. 57 of them (64%) were treated with voriconazole. 21%
of them were\2 yrs, 47% 2-12-yrs and 32 % .12 yrs.
